Most cited papers from Celon Pharma (Poland)

Celon Pharma (Poland)

What are the most cited papers from Celon Pharma (Poland)?

The most cited paper from Celon Pharma (Poland) is "Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial" (Jonathan M. Spergel, Marc E. Rothenberg, Margaret H. Collins et al., 2011), with 556 citations. Next come "Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer" (81) and "Prognostic Significance of Wnt-1, β-catenin and E-cadherin Expression in Advanced Colorectal Carcinoma" (78).

Published TypeFieldAccess

Showing 50 of 60 papers. Every paper with more than 4 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Reslizumab in children and adolescents with eosinophilic esophagitis: Results of a double-blind, randomized, placebo-controlled trial Jonathan M. Spergel, Marc E. Rothenberg, Margaret H. Collins et al. · Journal of Allergy and Clinical Immunology	30 Dec 2011	556
2	Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer Lubomir Bodnar, Aleksandra M. Stanczak, Szczepan Cierniak et al. · Journal of Ovarian Research Open access	2014	81
3	Prognostic Significance of Wnt-1, β-catenin and E-cadherin Expression in Advanced Colorectal Carcinoma Aleksandra M. Stanczak, Rafał Stec, Lubomir Bodnar et al. · Pathology & Oncology Research Open access	15 Jun 2011	78
4	Epithelial–mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells Paulina Grygielewicz, Barbara Dymek, Anna Bujak et al. · Gastric Cancer Open access	19 Nov 2014	72
5	Quality by Design (QbD) and Design of Experiments (DOE) as a Strategy for Tuning Lipid Nanoparticle Formulations for RNA Delivery Lidia Gurba-Bryśkiewicz, Wioleta Maruszak, Damian A. Smuga et al. · Biomedicines Open access	11 Oct 2023	63
6	Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1–3) Abdellah Yamani, Daria Zdżalik-Bielecka, Joanna Lipner et al. · European Journal of Medicinal Chemistry Open access	6 Nov 2020	46
7	Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists Piotr Pankiewicz et al. · Pharmaceuticals Open access	21 Jul 2021	43
8	MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells Kamila Kitowska, Monika Gorska‐Arcisz, Dima Antoun et al. · Frontiers in Oncology Open access	7 Apr 2021	43
9	Virtual screening-driven discovery of dual 5-HT6/5-HT2A receptor ligands with pro-cognitive properties Jakub Staroń, Rafał Kurczab, Dawid Warszycki et al. · European Journal of Medicinal Chemistry Open access	7 Nov 2019	38
10	Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma Daria Zdżalik-Bielecka, Barbara Dymek, Paulina Grygielewicz et al. · Journal of Cancer Research and Clinical Oncology Open access	7 Feb 2014	37
11	Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells Maciej Wieczorek, Aleksandra Paczkowska, Piotr Guzenda et al. · Cancer Biology & Therapy Open access	4 Feb 2008	36
12	Characterization of the Heat-Stable Proteome during Seed Germination in Arabidopsis with Special Focus on LEA Proteins Orarat Ginsawaeng, Michał Górka, Alexander Erban et al. · International Journal of Molecular Sciences Open access	29 Jul 2021	31
13	In vitro findings of alterations in intracellular calcium homeostasis in schizophrenia Łukasz Bojarski, Katarzyna Debowska, Urszula Wojda · Progress in Neuro-Psychopharmacology and Biological Psychiatry	Sep 2010	27
14	Synthesis and characterization of novel classes of PDE10A inhibitors - 1H-1,3-benzodiazoles and imidazo[1,2-a]pyrimidines Rafał Moszczyński-Pętkowski, Jakub Majer, Małgorzata Borkowska et al. · European Journal of Medicinal Chemistry Open access	30 May 2018	26
15	Dual Piperidine-Based Histamine H 3 and Sigma-1 Receptor Ligands in the Treatment of Nociceptive and Neuropathic Pain Katarzyna Szczepańska et al. · Journal of Medicinal Chemistry Open access	7 Jul 2023	22
16	2-Aminoimidazole-based antagonists of the 5-HT6 receptor – A new concept in aminergic GPCR ligand design Adam S. Hogendorf et al. · European Journal of Medicinal Chemistry Open access	5 Jun 2019	21
17	Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy Agata Mikołajczyk, Filip Mituła, Delfina Popiel et al. · Cancers Open access	18 May 2022	18
18	From NMR to AI: Designing a Novel Chemical Representation to Enhance Machine Learning Predictions of Physicochemical Properties Arkadiusz Leniak, Wojciech Pietruś, Rafał Kurczab · Journal of Chemical Information and Modeling	26 Mar 2024	17
19	HPLC method for simultaneous determination of salmeterol xinafoate and fluticasone propionate for the quality control of dry powder inhalation products Edyta Carrion Paczkowska, D. Smukowska, Ewa Tratkiewicz et al. · Acta Chromatographica Open access	12 Apr 2014	17
20	microRNA-449a reduces growth hormone-stimulated senescent cell burden through PI3K-mTOR signaling Sarah A. Noureddine, Jia Nie, Augusto Schneider et al. · Proceedings of the National Academy of Sciences Open access	28 Mar 2023	16
21	Pyrroloquinoline scaffold-based 5-HT6R ligands: Synthesis, quantum chemical and molecular dynamic studies, and influence of nitrogen atom position in the scaffold on affinity Katarzyna Grychowska, Rafał Kurczab, Paweł Śliwa et al. · Bioorganic & Medicinal Chemistry Open access	23 May 2018	16
22	How does the order of sample analysis influence the matrix effect during LC-MS bioanalysis? Elżbieta Gniazdowska, Joanna Giebułtowicz, Piotr J. Rudzki · Journal of Chromatography B	24 Jun 2023	15
23	Implementation of QbD Approach to the Development of Chromatographic Methods for the Determination of Complete Impurity Profile of Substance on the Preclinical and Clinical Step of Drug Discovery Studies Lidia Gurba-Bryśkiewicz, Urszula Dawid, Damian A. Smuga et al. · International Journal of Molecular Sciences Open access	14 Sep 2022	15
24	Esketamine inhaled as dry powder: Pharmacokinetic, pharmacodynamic and safety assessment in a preclinical study Mikołaj Matłoka, Sylwia Janowska, Anna Gajos‐Draus et al. · Pulmonary Pharmacology & Therapeutics	14 Apr 2022	14
25	Discovery and development of CPL207280 as new GPR40/FFA1 agonist Mateusz Mach, Katarzyna Bazydło‐Guzenda, Paweł Buda et al. · European Journal of Medicinal Chemistry	Sep 2021	14
26	A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus Maria Gabriela Dulak-Lis, Anna Bujak, Kamila Gala et al. · Journal of Pharmacological Sciences Open access	9 Feb 2021	14
27	Distinct cognitive and discriminative stimulus effects of ketamine enantiomers in rats Piotr Popik, Shaun Yon‐Seng Khoo, Agata Kuziak et al. · Pharmacology Biochemistry and Behavior Open access	3 Aug 2020	14
28	Antiparkinsonian-like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease Tomasz Lenda, Krystyna Ossowska, Klemencja Berghauzen-Maciejewska et al. · European Journal of Pharmacology Open access	29 Aug 2021	12
29	From NMR to AI: Do We Need 1 H NMR Experimental Spectra to Obtain High-Quality logD Prediction Models? Arkadiusz Leniak, Wojciech Pietruś, Aleksandra Świderska et al. · Journal of Chemical Information and Modeling Open access	5 Mar 2025	11
30	FGFR1–4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer Joanna Moes-Sosnowska, Monika Skupińska, Urszula Lechowicz et al. · International Journal of Molecular Sciences Open access	10 Sep 2022	10
31	Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II—Benzimidazole Derivatives Mariola Stypik et al. · Pharmaceuticals Open access	27 Jul 2022	10
32	Results from Genetic Studies in Patients Affected with Craniosynostosis: Clinical and Molecular Aspects Ewelina Bukowska‐Olech, Anna Sowińska‐Seidler, Dawid Larysz et al. · Frontiers in Molecular Biosciences Open access	28 Apr 2022	10
33	p38 Mediates Resistance to FGFR Inhibition in Non-Small Cell Lung Cancer Izabela Zarczynska, Monika Gorska‐Arcisz, Alexander Jorge Cortez et al. · Cells Open access	30 Nov 2021	10
34	Spatiotemporal Analysis of Hydration Mechanism in Sodium Alginate Matrix Tablets Ewelina Juszczyk, Piotr Kulinowski, Ewelina Baran et al. · Materials Open access	30 Jan 2021	10
35	Identification and characterization of aptameric inhibitors of human neutrophil elastase Stanisłąw Malicki, Mirosław Książęk, Alicja Sochaj Gregorczyk et al. · Journal of Biological Chemistry Open access	5 Jun 2023	9
36	A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects Mikołaj Matłoka, Sylwia Janowska, Piotr Pankiewicz et al. · Frontiers in Pharmacology Open access	9 Nov 2022	9
37	Hydration Patterns in Sodium Alginate Polymeric Matrix Tablets—The Result of Drug Substance Incorporation Ewelina Juszczyk, Piotr Kulinowski, Ewelina Baran et al. · Materials Open access	29 Oct 2021	9
38	Quetiapine and novel PDE10A inhibitors potentiate the anti-BuChE activity of donepezil Joanna Sikora, Maria Podsiedlik, Tadeusz Pietras et al. · Journal of Enzyme Inhibition and Medicinal Chemistry Open access	2020	9
39	Simultaneous 5-HT1BR agonist/5-HT6R antagonist action as a potential treatment of Parkinson’s disease and its comorbidities Paweł Zajdel et al. · Journal of Pharmacology and Experimental Therapeutics Open access	10 Dec 2024	8
40	The design of experiments (DoE) in optimization of an aerobic flow Pd-catalyzed oxidation of alcohol towards an important aldehyde precursor in the synthesis of phosphatidylinositide 3-kinase inhibitor (CPL302415) Stanisław Michałek, Lidia Gurba-Bryśkiewicz, Wioleta Maruszak et al. · RSC Advances Open access	2022	8
41	Early synaptic deficits in GSK-3β overexpressing mice Ewa Banach, Tomasz Jaworski, Joanna Urban‐Ciećko · Neuroscience Letters	16 Jun 2022	8
42	Replicates Number for Drug Stability Testing during Bioanalytical Method Validation—An Experimental and Retrospective Approach Elżbieta Gniazdowska, Wojciech Goch, Joanna Giebułtowicz et al. · Molecules Open access	11 Jan 2022	7
43	Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma Paweł Gunerka, Kamila Gala, Martyna Banach et al. · PLoS ONE Open access	23 Jul 2020	7
44	Safety and pharmacokinetics study of inhaled esketamine after a single dose in healthy volunteers Sylwia Janowska, Ewa Tratkiewicz, Mikołaj Matłoka et al. · European Neuropsychopharmacology	2019	7
45	Cell-based assay for low- and high-scale screening of the Wnt/β-catenin signaling modulators Maria Mazur, Anna Bujak, Mikołaj Matłoka et al. · Analytical Biochemistry	7 Feb 2015	7
46	Hydroxysteroid 17-β dehydrogenase 14 (HSD17B14) is an L-fucose dehydrogenase, the initial enzyme of the L-fucose degradation pathway Apolonia Witecka, Varvara Kazak, S. Kwiatkowski et al. · Journal of Biological Chemistry Open access	27 Jun 2024	6
47	Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer Delfina Popiel et al. · Frontiers in Oncology Open access	12 Jan 2024	6
48	Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey Katarzyna Bazydło‐Guzenda, Paweł Buda, Mateusz Mach et al. · PLoS ONE Open access	23 Sep 2021	6
49	Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial Ewelina Juszczyk, Kamil Kisło, Paweł Żero et al. · Pharmaceutics Open access	28 May 2021	6
50	Discovery of TRAF-2 and NCK-interacting kinase (TNIK) inhibitors by ligand-based virtual screening methods Anna Bujak, Filip Stefaniak, Daria Zdżalik-Bielecka et al. · MedChemComm	2015	6

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.